These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29280349)

  • 1. Translational model to predict pulmonary pharmacokinetics and efficacy in man for inhaled bronchodilators.
    Hendrickx R; Lamm Bergström E; Janzén DLI; Fridén M; Eriksson U; Grime K; Ferguson D
    CPT Pharmacometrics Syst Pharmacol; 2018 Mar; 7(3):147-157. PubMed ID: 29280349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Accurately Predicts the Better Bronchodilatory Effect of Inhaled Versus Oral Salbutamol Dosage Forms.
    Boger E; Fridén M
    J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):1-12. PubMed ID: 29878860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benchmarking of Human Dose Prediction for Inhaled Medicines from Preclinical In Vivo Data.
    Ericsson T; Fridén M; Kärrman-Mårdh C; Dainty I; Grime K
    Pharm Res; 2017 Dec; 34(12):2557-2567. PubMed ID: 28685298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats.
    Jones RM; Harrison A
    Xenobiotica; 2012 Jan; 42(1):75-85. PubMed ID: 22077102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systems Pharmacology Approach for Prediction of Pulmonary and Systemic Pharmacokinetics and Receptor Occupancy of Inhaled Drugs.
    Boger E; Evans N; Chappell M; Lundqvist A; Ewing P; Wigenborg A; Fridén M
    CPT Pharmacometrics Syst Pharmacol; 2016 Apr; 5(4):201-10. PubMed ID: 27104089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A geometrical approach to the PKPD modelling of inhaled bronchodilators.
    Gaz C; Cremona G; Panunzi S; Patterson B; De Gaetano A
    J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):415-28. PubMed ID: 22801773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A non-parametric method to analyse time-course of effect in the absence of pharmacokinetic data: application to inhaled bronchodilators.
    Agoram BM; Milligan PA; van der Graaf PH
    Eur J Pharm Sci; 2008 Aug; 34(4-5):250-6. PubMed ID: 18547791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease.
    Matera MG; Rinaldi B; Page C; Rogliani P; Cazzola M
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1101-1111. PubMed ID: 30261755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach.
    Weber B; Hochhaus G
    AAPS J; 2015 Jul; 17(4):999-1010. PubMed ID: 25933600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
    Ramadan WH; Kabbara WK; El Khoury GM; Al Assir SA
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2347-56. PubMed ID: 26586940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler.
    Van Holsbeke C; De Backer J; Vos W; Marshall J
    Ther Adv Respir Dis; 2018; 12():1753466618760948. PubMed ID: 29499614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
    Kerwin EM; Siler TM; Arora S; Darken P; Rose E; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1483-1494. PubMed ID: 29773947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
    Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
    Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The fate of inhaled drugs: the pharmacokinetics and pharmacodynamics of drugs administered by aerosol.
    Witek TJ
    Respir Care; 2000 Jul; 45(7):826-30. PubMed ID: 10926379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting inhaled bronchodilators in COPD: how many drugs do we need?
    Calverley PM
    Eur Respir J; 2005 Aug; 26(2):190-1. PubMed ID: 16055864
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung.
    Minto C; Li B; Tattam B; Brown K; Seale JP; Donnelly R
    Br J Clin Pharmacol; 2000 Aug; 50(2):116-24. PubMed ID: 10930963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Experimental and Mathematical Approaches for Assessing Effective Doses of Inhaled Drugs, Using Mometasone to Support Human Dose Predictions.
    Caniga M; Cabal A; Mehta K; Ross DS; Gil MA; Woodhouse JD; Eckman J; Naber JR; Callahan MK; Goncalves L; Hill SE; Mcleod RL; McIntosh F; Freke MC; Visser SA; Johnson N; Salmon M; Cicmil M
    J Aerosol Med Pulm Drug Deliv; 2016 Aug; 29(4):362-77. PubMed ID: 26859446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models.
    Pulido-Rios MT; McNamara A; Obedencio GP; Ji Y; Jaw-Tsai S; Martin WJ; Hegde SS
    J Pharmacol Exp Ther; 2013 Aug; 346(2):241-50. PubMed ID: 23685545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equivalent Lung Dose and Systemic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler.
    Lähelmä S; Sairanen U; Haikarainen J; Korhonen J; Vahteristo M; Fuhr R; Kirjavainen M
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):462-73. PubMed ID: 25757188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline.
    Ewing P; Eirefelt SJ; Andersson P; Blomgren A; Ryrfeldt A; Gerde P
    J Aerosol Med Pulm Drug Deliv; 2008 Jun; 21(2):169-80. PubMed ID: 18518793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.